Maxime Cormier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maxime Cormier has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Schwartzman
McGill International Tuberculosis Centre, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
2 shared publications Aashna Uppal
Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, Respiratory Division, McGill University, Montreal, QC, Canada
1 shared publicationAlexandre M dos Santos
Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, Respiratory Division, McGill University, Montreal, QC, Canada
1 shared publicationC. Lemière
Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal, Hôpital du Sacré Cœur de Montréal, Université de Montréal, Montréal, QC, Canada
1 shared publication- Catherine Lemiere
CIUSSS du Nord-de-l'île-de-Montréal; Université de Montréal
1 shared publication Claire E Boone
Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, Respiratory Division, McGill University, Montreal, QC, Canada
1 shared publication
Latest Publications
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4981
Oscillometry and Spirometry in Fibrotic Versus Non-fibrotic Interstitial Lung Disease
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4981
Oscillometry and Spirometry in Fibrotic Versus Non-fibrotic Interstitial Lung Disease
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 736-738
Secondary loss of response to mepolizumab in severe eosinophilic asthma
- 1 February 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (2) , 736-738
Secondary loss of response to mepolizumab in severe eosinophilic asthma
- 1 January 2020
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 24 (1) , 8-21
Occupational asthma
Work-related asthma is highly prevalent and represents a significant societal and financial burden worldwide. This State of the Art series article explores the epidemiology, clinical features, diagnosis and management of occupational asthma (OA), which comprises sensitiser-induced asthma and irritant-induced asthma (IIA). Sensitiser-induced OA is the development of asthma through sensitisation to a substance in the workplace. OA is largely underdiagnosed, and its clinical manifestations are non-specific, which makes its diagnosis challenging. Early and accurate diagnosis of OA through comprehensive testing is primordial to avoid unwarranted removal from exposure and to allow early management of confirmed cases. Despite optimal management, up to 70% of patients with OA will have persistent asthma several years after diagnosis. IIA classically refers to the development of de novo asthma acutely following an intense exposure to an irritant agent. However, some cases of IIA following multiple high-level exposures or a chronic low-dose exposure have been reported.
- 1 January 2020
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 24 (1) , 8-21
Occupational asthma
Work-related asthma is highly prevalent and represents a significant societal and financial burden worldwide. This State of the Art series article explores the epidemiology, clinical features, diagnosis and management of occupational asthma (OA), which comprises sensitiser-induced asthma and irritant-induced asthma (IIA). Sensitiser-induced OA is the development of asthma through sensitisation to a substance in the workplace. OA is largely underdiagnosed, and its clinical manifestations are non-specific, which makes its diagnosis challenging. Early and accurate diagnosis of OA through comprehensive testing is primordial to avoid unwarranted removal from exposure and to allow early management of confirmed cases. Despite optimal management, up to 70% of patients with OA will have persistent asthma several years after diagnosis. IIA classically refers to the development of de novo asthma acutely following an intense exposure to an irritant agent. However, some cases of IIA following multiple high-level exposures or a chronic low-dose exposure have been reported.
- Open Access
- 1 January 2019
- Published by Elsevier in The Lancet Global Health
- Vol. 7 (1) , e68-e80
Proximate determinants of tuberculosis in Indigenous peoples worldwide: a systematic review
- 1 January 2019
- Published by Elsevier in The Lancet Global Health
- Vol. 7 (1) , e68-e80
Open AccessProximate determinants of tuberculosis in Indigenous peoples worldwide: a systematic review
- 1 February 2017
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 177 (2) , 266
Chest Pain and Supplemental Oxygen
- 1 February 2017
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 177 (2) , 266
Chest Pain and Supplemental Oxygen
- Open Access
- 5 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0154825
Latent Tuberculosis in Pregnancy: A Systematic Review
In countries with low tuberculosis (TB) incidence, immigrants from higher incidence countries represent the major pool of individuals with latent TB infection (LTBI). The antenatal period represents an opportunity for immigrant women to access the medical system, and hence for potential screening and treatment of LTBI. However, such screening and treatment during pregnancy remains controversial. In order to further understand the prevalence, natural history, screening and management of LTBI in pregnancy, we conducted a systematic literature review addressing the screening and treatment of LTBI, in pregnant women without known HIV infection. A systematic review of 4 databases (Embase, Embase Classic, Medline, Cochrane Library) covering articles published from January 1st 1980 to April 30th 2014. Articles in English, French or Spanish with relevant information on prevalence, natural history, screening tools, screening strategies and treatment of LTBI during pregnancy were eligible for inclusion. Articles were excluded if (1) Full text was not available (2) they were case series or case studies (3) they focused exclusively on prevalence, diagnosis and treatment of active TB (4) the study population was exclusively HIV-infected. Of 4,193 titles initially identified, 208 abstracts were eligible for review. Of these, 30 articles qualified for full text review and 22 were retained: 3 cohort studies, 2 case-control studies, and 17 cross-sectional studies. In the USA, the estimated prevalence of LTBI ranged from 14 to 48% in women tested, and tuberculin skin test (TST) positivity was associated with ethnicity. One study suggested that incidence of active TB was significantly increased during the 180 days postpartum (Incidence rate ratio, 1.95 (95% CI 1.24–3.07). There was a high level of adherence with both skin testing (between 90–100%) and chest radiography (93–100%.). In three studies from low incidence settings, concordance between TST and an interferon-gamma release assay was 77, 88 and 91% with kappa values ranging from 0.26 to 0.45. In low incidence settings, an IGRA may be more specific and less sensitive than TST, and results do not appear to be altered by pregnancy. The proportion of women who attended follow-up visits after positive tuberculin tests varied from 14 to 69%, while 5 to 42% of those who attended follow-up visits completed a minimum of 6 months of isoniazid treatment. One study raised the possibility of an association of pregnancy/post-partum state with INH hepatitis (risk ratio 2,5, 95% CI 0.8–8.2) and fatal hepatotoxicity (rate ratio 4.0, 95% CI 0.2–258). One study deemed INH safe during breastfeeding based on peak concentrations in plasma and breast milk after INH administration. Pregnancy is an opportunity to screen for LTBI. Interferon-gamma release assays are likely comparable to tuberculin skin tests and may be used during pregnancy. Efforts should be made to improve adherence with follow-up and treatment post-partum. Further data are needed with respect to safety and feasibility of antepartum INH therapy, and with respect to alternative treatment regimens.
- 5 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0154825
Open AccessLatent Tuberculosis in Pregnancy: A Systematic Review
In countries with low tuberculosis (TB) incidence, immigrants from higher incidence countries represent the major pool of individuals with latent TB infection (LTBI). The antenatal period represents an opportunity for immigrant women to access the medical system, and hence for potential screening and treatment of LTBI. However, such screening and treatment during pregnancy remains controversial. In order to further understand the prevalence, natural history, screening and management of LTBI in pregnancy, we conducted a systematic literature review addressing the screening and treatment of LTBI, in pregnant women without known HIV infection. A systematic review of 4 databases (Embase, Embase Classic, Medline, Cochrane Library) covering articles published from January 1st 1980 to April 30th 2014. Articles in English, French or Spanish with relevant information on prevalence, natural history, screening tools, screening strategies and treatment of LTBI during pregnancy were eligible for inclusion. Articles were excluded if (1) Full text was not available (2) they were case series or case studies (3) they focused exclusively on prevalence, diagnosis and treatment of active TB (4) the study population was exclusively HIV-infected. Of 4,193 titles initially identified, 208 abstracts were eligible for review. Of these, 30 articles qualified for full text review and 22 were retained: 3 cohort studies, 2 case-control studies, and 17 cross-sectional studies. In the USA, the estimated prevalence of LTBI ranged from 14 to 48% in women tested, and tuberculin skin test (TST) positivity was associated with ethnicity. One study suggested that incidence of active TB was significantly increased during the 180 days postpartum (Incidence rate ratio, 1.95 (95% CI 1.24–3.07). There was a high level of adherence with both skin testing (between 90–100%) and chest radiography (93–100%.). In three studies from low incidence settings, concordance between TST and an interferon-gamma release assay was 77, 88 and 91% with kappa values ranging from 0.26 to 0.45. In low incidence settings, an IGRA may be more specific and less sensitive than TST, and results do not appear to be altered by pregnancy. The proportion of women who attended follow-up visits after positive tuberculin tests varied from 14 to 69%, while 5 to 42% of those who attended follow-up visits completed a minimum of 6 months of isoniazid treatment. One study raised the possibility of an association of pregnancy/post-partum state with INH hepatitis (risk ratio 2,5, 95% CI 0.8–8.2) and fatal hepatotoxicity (rate ratio 4.0, 95% CI 0.2–258). One study deemed INH safe during breastfeeding based on peak concentrations in plasma and breast milk after INH administration. Pregnancy is an opportunity to screen for LTBI. Interferon-gamma release assays are likely comparable to tuberculin skin tests and may be used during pregnancy. Efforts should be made to improve adherence with follow-up and treatment post-partum. Further data are needed with respect to safety and feasibility of antepartum INH therapy, and with respect to alternative treatment regimens.